Depreciation of VACCINEX, INC. from 31 Dec 2017 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
VACCINEX, INC. quarterly and annual Depreciation in USD history and change rate from 31 Dec 2017 to 31 Dec 2024.
  • VACCINEX, INC. Depreciation for the quarter ending 31 Dec 2024 was $18,000, a 33% decline year-over-year.
  • VACCINEX, INC. Depreciation for the twelve months ending 31 Dec 2024 was $94,000, a 21% decline year-over-year.
  • VACCINEX, INC. annual Depreciation for 2024 was $94,000, a 21% decline from 2023.
  • VACCINEX, INC. annual Depreciation for 2023 was $119,000, a 43% decline from 2022.
  • VACCINEX, INC. annual Depreciation for 2022 was $207,000, a 22% increase from 2021.
Source SEC data
View on sec.gov
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Change (%)
Depreciation, Annual (USD)
Depreciation, YoY Annual Change (%)

VACCINEX, INC. Quarterly Depreciation (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $94,000 $18,000 -$9,000 -33% 01 Oct 2024 31 Dec 2024 10-K 15 Apr 2025 2024 FY
Q3 2024 $103,000 $24,000 -$7,000 -23% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2024 2024 Q3
Q2 2024 $110,000 $25,000 -$5,000 -17% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2024 2024 Q2
Q1 2024 $115,000 $27,000 -$4,000 -13% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2024 2024 Q1
Q4 2023 $119,000 $27,000 -$18,000 -40% 01 Oct 2023 31 Dec 2023 10-K 15 Apr 2025 2024 FY
Q3 2023 $137,000 $31,000 -$36,000 -54% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $173,000 $30,000 -$24,000 -44% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q1 2023 $197,000 $31,000 -$10,000 -24% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q4 2022 $207,000 $45,000 +$3,000 +7.1% 01 Oct 2022 31 Dec 2022 10-K/A 25 Apr 2024 2023 FY
Q3 2022 $204,000 $67,000 +$30,000 +81% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $174,000 $54,000 +$19,000 +54% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $155,000 $41,000 -$14,000 -25% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $169,000 $42,000 -$29,000 -41% 01 Oct 2021 31 Dec 2021 10-K 31 Mar 2023 2022 FY
Q3 2021 $198,000 $37,000 -$37,000 -50% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $235,000 $35,000 -$52,000 -60% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q1 2021 $287,000 $55,000 -$20,000 -27% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q4 2020 $307,000 $71,000 +$3,000 +4.4% 01 Oct 2020 31 Dec 2020 10-K 31 Mar 2022 2021 FY
Q3 2020 $304,000 $74,000 +$10,000 +16% 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021 2021 Q3
Q2 2020 $294,000 $87,000 +$30,000 +53% 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021 2021 Q2
Q1 2020 $264,000 $75,000 +$15,000 +25% 01 Jan 2020 31 Mar 2020 10-Q 17 May 2021 2021 Q1
Q4 2019 $249,000 $68,000 01 Oct 2019 31 Dec 2019 10-K 31 Mar 2021 2020 FY
Q3 2019 $64,000 01 Jul 2019 30 Sep 2019 10-Q 13 Nov 2020 2020 Q3
Q2 2019 $57,000 01 Apr 2019 30 Jun 2019 10-Q 14 Aug 2020 2020 Q2
Q1 2019 $60,000 01 Jan 2019 31 Mar 2019 10-Q 14 May 2020 2020 Q1

VACCINEX, INC. Annual Depreciation (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $94,000 -$25,000 -21% 01 Jan 2024 31 Dec 2024 10-K 15 Apr 2025 2024 FY
2023 $119,000 -$88,000 -43% 01 Jan 2023 31 Dec 2023 10-K 15 Apr 2025 2024 FY
2022 $207,000 +$38,000 +22% 01 Jan 2022 31 Dec 2022 10-K/A 25 Apr 2024 2023 FY
2021 $169,000 -$138,000 -45% 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2023 2022 FY
2020 $307,000 +$58,000 +23% 01 Jan 2020 31 Dec 2020 10-K 31 Mar 2022 2021 FY
2019 $249,000 +$26,000 +12% 01 Jan 2019 31 Dec 2019 10-K 31 Mar 2021 2020 FY
2018 $223,000 +$17,000 +8.3% 01 Jan 2018 31 Dec 2018 10-K 09 Mar 2020 2019 FY
2017 $206,000 01 Jan 2017 31 Dec 2017 10-K 13 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.